
Dermatology Times February 2025 Recap
Clearances, Approvals, Updates, and Recommendations Rezpegaldesleukin Receives Fast Track Designation for Moderate to Severe AD Nektar Therapeutics’ investigational biologic targets the IL-2 receptor complex. FDA Accepts sBLA for Dupilumab as Potential BP …